1-(Diaminomethylidene)-2-[3-(propylamino)propyl]guanidine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(Diaminomethylidene)-2-[3-(propylamino)propyl]guanidine
• 英文别名: 1-(diaminomethylidene)-2-[3-(propylamino)propyl]guanidine
• 化学式: C₈H₂₀N₆
• 分子量: 200.29
• InChiKey: NYKLVALTOKUZHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  115
• 氢给体数：
  4
• 氢受体数：
  2

文献信息

• [EN] SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME<br/>[FR] INHIBITEURS SÉLECTIFS DE L'INFLAMMASOME NLRP3
  申请人：NODTHERA LTD

  公开号：WO2019025467A1

  公开（公告）日：2019-02-07

  The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.

  本公开涉及式(I)化合物：(I)；及其药用可接受盐、药物组合物、使用方法和制备方法。所公开的化合物可用于通过抑制炎症小体来抑制IL-1家族细胞因子的成熟，并可用于治疗炎症小体活性涉及的疾病，如自炎性和自身免疫疾病以及癌症。
• [EN] ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION<br/>[FR] INHIBITEURS CHROMÉNONE ALLOSTÉRIQUES DE LA PHOSPHOINOSITIDE 3-KINASE (PI3K) POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À LA MODULATION DE PI3K
  申请人：PETRA PHARMA CORP

  公开号：WO2021202964A1

  公开（公告）日：2021-10-07

  The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I), or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.

  该披露涉及到式(I)的化合物，作为磷脂酰肌醇3-激酶（PI3K）的变构色酮抑制剂，在与PI3K调节相关的疾病或紊乱的治疗中有用，式(I)，或其前药、溶剂化合物、对映体、立体异构体、互变异构体或其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、W、X、Y、s和环A如本文所述。
• [EN] QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS DE QUINOLIN-4-ONE ET DE 4(1H)-CINNOLINONE ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：FREQUENCY THERAPEUTICS INC

  公开号：WO2020163816A1

  公开（公告）日：2020-08-13

  The present disclosure relates to quinolin-4-one and 4(1H)-cinnolinone compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into tissue cells.

  本公开涉及喹啉-4-酮和4(1H)-喹啉酮化合物，以及使用它们诱导干/祖细胞支持细胞自我更新的方法，包括诱导干/祖细胞增殖，同时在子细胞中保持分化为组织细胞的能力。
• [EN] SULFONYLUREA DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE SULFONYLURÉE ET LEURS UTILISATIONS
  申请人：NODTHERA LTD

  公开号：WO2020249664A1

  公开（公告）日：2020-12-17

  The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

  本公开涉及式(I)化合物及其前药、药用可接受盐、药物组合物、使用方法和制备方法。所公开的化合物可用于通过抑制炎症小体来抑制IL-1家族细胞因子的成熟，并可用于治疗炎症、自身炎症和自身免疫疾病以及癌症等炎症小体活性涉及的疾病。
• [EN] DIMERIC COMPOUNDS AS STING AGONISTS<br/>[FR] COMPOSÉS DIMÈRES UTILISÉS EN TANT QU'AGONISTES DE STING
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2021113679A1

  公开（公告）日：2021-06-10

  The present disclosure relates to dimeric STING agonists of Formulae (I), (II), (III), (IV), (V), and (VI), and pharmaceutically acceptable salts thereof. The present disclosure also relates to methods of preparing the compounds and methods of using the compounds.

  本公开涉及以下公式(I)、(II)、(III)、(IV)、(V)和(VI)的二聚体STING激动剂及其药用可接受盐。本公开还涉及制备这些化合物的方法以及使用这些化合物的方法。